Werewolf Total Assets from 2010 to 2026
| HOWL Stock | USD 0.62 0.04 5.44% |
Total Assets | First Reported 2020-12-31 | Previous Quarter 92.6 M | Current Value 79.6 M | Quarterly Volatility 37.9 M |
Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Depreciation And Amortization of 1.1 M or Interest Expense of 5.6 M, as well as many indicators such as Price To Sales Ratio of 32.15, Dividend Yield of 0.0 or PTB Ratio of 0.95. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
Werewolf | Total Assets | Build AI portfolio with Werewolf Stock |
Historical Total Assets data for Werewolf Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Werewolf Therapeutics represents a compelling investment opportunity.
Latest Werewolf Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Werewolf Therapeutics over the last few years. Total assets refers to the total amount of Werewolf Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Werewolf Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Werewolf Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Werewolf Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 126.93 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Werewolf Total Assets Regression Statistics
| Arithmetic Mean | 72,919,093 | |
| Geometric Mean | 47,198,769 | |
| Coefficient Of Variation | 89.91 | |
| Mean Deviation | 60,282,463 | |
| Median | 21,679,000 | |
| Standard Deviation | 65,561,594 | |
| Sample Variance | 4298.3T | |
| Range | 157.6M | |
| R-Value | 0.83 | |
| Mean Square Error | 1444.5T | |
| R-Squared | 0.68 | |
| Significance | 0.000041 | |
| Slope | 10,745,020 | |
| Total Sum of Squares | 68773.2T |
Werewolf Total Assets History
Other Fundumenentals of Werewolf Therapeutics
Werewolf Therapeutics Total Assets component correlations
Click cells to compare fundamentals
About Werewolf Therapeutics Financial Statements
Werewolf Therapeutics investors utilize fundamental indicators, such as Total Assets, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 146 M | 139.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Werewolf Therapeutics Correlation against competitors. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.